Skip to main content
SpringerLink
Log in

The role of gemtuzumab ozogamicin in combination chemotherapy regimens for primary resistant or relapsed acute myeloid leukemia

  • Clinical Trials Report
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Stanisic S, Kalaycio M: Treatment of refractory and relapsed acute myelogenous leukemia. Expert Rev Anticancer Ther 2002, 2: 287–295.

    Article  PubMed  CAS  Google Scholar 

  2. Tallman S, McDonald GB, DeLeve LD, et al.: Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin, GO): a prospective observational study in routine clinical practice [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112: 956.

    Google Scholar 

  3. Attal M, Huguet F, Rubie H, et al.: Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 1992, 79: 1–7.

    Google Scholar 

  4. Simon M, Hahn T, Ford LA, et al.: Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin. Bone Marrow Transplant 2001, 27: 627–633.

    Article  PubMed  CAS  Google Scholar 

  5. Carreras E, Bertz H, Arcese W, et al.: Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. Blood 1998, 10: 3599–3604.

    Google Scholar 

Download references

Authors
  1. Hien K. Duong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matt Kalaycio
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Duong, H.K., Kalaycio, M. The role of gemtuzumab ozogamicin in combination chemotherapy regimens for primary resistant or relapsed acute myeloid leukemia. Curr Hematol Malig Rep 4, 55–56 (2009). https://doi.org/10.1007/s11899-009-0008-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-009-0008-3

Keywords

Search

Navigation